Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review

被引：7
|
作者：
Elsbernd, Paul M. [1 ]
Carter, Jonathan L. [1 ]
机构：
[1] Mayo Clin, Dept Neurol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA
来源：
BIOLOGICS-TARGETS & THERAPY | 2021年 / 15卷
关键词：
monoclonal antibodies; multiple sclerosis; relapsing; progressive; review; NATALIZUMAB ANTIBODIES; INTERFERON BETA-1A; CONTROLLED TRIAL; RISK; ALEMTUZUMAB; RITUXIMAB; OCRELIZUMAB; PLACEBO; MECHANISMS; SAFETY;
D O I：
10.2147/BTT.S267273
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Monoclonal antibody therapies have secured an important role in the therapeutic landscape for the treatment of both relapsing and progressive forms of multiple sclerosis due to their potent efficacy, convenient dosing schedules, and well-defined side effect profiles. Each therapy has unique risks and benefits associated with its specific mechanism of action which ultimately guides clinical decision-making for individual patients. This review will summarize the mechanisms of action, evidence leading to their approval, and clinically relevant considerations for each of the current monoclonal antibody therapies approved for the treatment of multiple sclerosis.
引用
收藏
页码：255 / 263
页数：9
相关论文
共 50 条
  • [1] Emerging monoclonal antibody therapies for multiple sclerosis
    Cree, Bruce
    NEUROLOGIST, 2006, 12 (04) : 171 - 178
  • [2] Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis
    Wootla, Bharath
    Watzlawik, Jens O.
    Stavropoulos, Nikolaos
    Wittenberg, Nathan J.
    Dasari, Harika
    Abdelrahim, Murtada A.
    Henley, John R.
    Oh, Sang-Hyun
    Warrington, Arthur E.
    Rodriguez, Moses
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (06) : 827 - 839
  • [3] Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis
    Xu, Xinghua
    Chi, Sumin
    Wang, Qun
    Li, Chengxin
    Xu, Bainan
    Zhang, Jun
    Chen, Xiaolei
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 25 : 322 - 328
  • [4] Extended dosing of monoclonal antibodies in multiple sclerosis
    Kempen, Zoe L. E. van
    Toorop, Alyssa A.
    Sellebjerg, Finn
    Giovannoni, Gavin
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (13) : 2001 - 2009
  • [5] Monoclonal Antibodies in Multiple Sclerosis: Present and Future
    Voge, Natalia V.
    Alvarez, Enrique
    BIOMEDICINES, 2019, 7 (01)
  • [6] Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Kim, Woojun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2020, 16 (03): : 355 - 368
  • [7] Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis
    De Giglio, Laura
    Grimaldi, Alessandro E.
    Fubelli, Federica
    Marinelli, Fabiana
    Pozzilli, Carlo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (05) : 417 - 429
  • [8] Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review
    Sharma, Kanika
    Tolaymat, Sarah
    Yu, Hongxuyang
    Elkhooly, Mahmoud
    Jaiswal, Shruti
    Jena, Anek
    Kakara, Mihir
    Sriwastava, Shitiz
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 443
  • [9] A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis
    Sabahi, Zahra
    Sorkhabi, Amin Daei
    Sarkesh, Aila
    Naseri, Amirreza
    Asghar-Rezaei, Nazli
    Talebi, Mahnaz
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 120
  • [10] A safety review of current monoclonal antibodies used to treat multiple sclerosis
    Costa, Gloria Dalla
    Comi, Giancarlo
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (11) : 1011 - 1024
12345